NCT00660920CompletedPhase 1
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies
Ariad Pharmaceuticals5 sites in 1 country81 target enrollmentStarted: June 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 81
- Locations
- 5
- Primary Endpoint
- Determine Maximum Tolerated Dose (MTD) or Recommended dose
Study Overview
Brief Summary
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or Female ≥ 18 years old
- •Diagnosed hematologic malignancy (other than lymphoma) that has relapsed or is refractory to standard care or for which no standard care is available or acceptable
- •Able to give written informed consent
- •ECOG performance status ≤ 2
- •BSA ≥ 1.5 m² (first cohort only)
- •Minimum life expectancy of 3 months or more
- •Adequate renal function defined as serum creatinine <1.5× upper limit of normal (ULN) for institution
- •Adequate hepatic function (defined as: Total bilirubin <1.5 × ULN for institution; ALT and AST <2.5 × ULN for institution [<5 X ULN if liver involvement with leukemia]; Prothrombin time <1.5 × ULN)
- •Ability to comply with study procedures in the Investigator's opinion
- •Adequate cardiac function defined as ejection fraction (EF) >40% by any method of the investigator's choice
- •Normal QTcF interval on screening ECG evaluation, defined as QTcF of <450 ms.
- •For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment
- •Female patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study
Exclusion Criteria
- •Have had cytotoxic chemotherapy or radiotherapy within 21 days prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 28 days earlier with the exception of alopecia
- •Received any other investigational agents or have received an investigational agent within 14 days of starting ponatinib
- •Malabsorption syndrome or other illness which could affect oral absorption
- •Significant uncontrolled cardiac disease
- •Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram.
- •Uncontrolled hypertension (Diastolic BP >100 mmHg; Systolic >150 mmHg)
- •Uncontrolled intercurrent illness
- •Known infection with HIV
- •Autologous or allogeneic stem cell transplant < 3 months prior to enrollment; any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy
- •Another primary malignancy within the past 3 years
- •Any condition or illness which, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the drug
- •Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram
- •Major surgery (with the exception of intravenous catheter placement or bone marrow biopsy) within 14 days prior to initiating ponatinib therapy
Arms & Interventions
ponatnib
Experimental
Comparison of different dosages of ponatinib given orally once per day.
Intervention: Ponatinib (Drug)
Outcomes
Primary Outcomes
Determine Maximum Tolerated Dose (MTD) or Recommended dose
Time Frame: Up to
Determine MTD dose or a recommended dose of oral ponatinib in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
Secondary Outcomes
- To describe potential pharmacogenomic markers of AP24534 anti-tumor activity(Up to 7 years)
- To examine the safety of AP24534 in patients with resistant/refractory hematologic malignancies(Up to 7 years)
- To describe the anti-tumor activity of AP24534 in patients with refractory hematologic malignancies(Up to 7 years)
- To examine pharmacodynamic activity of AP24534 in CML and Ph + ALL patients(Up to 7 years)
- To examine the pharmacokinetics of AP24534(Up to 2 cycles (1 cycle = 28 days))
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Recruiting
Phase 1
IKS014 in Advanced Solid Tumors That Express HER2Gastroesophageal-junction CancerBreast CancerGastric CancerNCT05872295Iksuda Therapeutics Ltd.165
Terminated
Phase 1
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic MalignanciesLymphomaNCT00460460AstraZeneca75
Completed
Phase 1
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT01103791Samyang Biopharmaceuticals Corporation19
Completed
Phase 1
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEpithelial Ovarian CancerNCT02480374Imunon18
Terminated
Phase 1
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6